235 related articles for article (PubMed ID: 21703309)
1. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
Yon C; Viswanathan P; Rossignol JF; Korba B
Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
[TBL] [Abstract][Full Text] [Related]
2. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF
Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524
[TBL] [Abstract][Full Text] [Related]
3. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
4. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Korba BE; Elazar M; Lui P; Rossignol JF; Glenn JS
Antimicrob Agents Chemother; 2008 Nov; 52(11):4069-71. PubMed ID: 18710916
[TBL] [Abstract][Full Text] [Related]
5. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
[TBL] [Abstract][Full Text] [Related]
8. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
[TBL] [Abstract][Full Text] [Related]
9. Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.
Cheng X; Gao XC; Wang JP; Yang XY; Wang Y; Li BS; Kang FB; Li HJ; Nan YM; Sun DX
World J Gastroenterol; 2014 Dec; 20(48):18284-95. PubMed ID: 25561795
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
Pfeiffer JK; Kirkegaard K
J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
15. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
[TBL] [Abstract][Full Text] [Related]
18. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.
Ikeda M; Yi M; Li K; Lemon SM
J Virol; 2002 Mar; 76(6):2997-3006. PubMed ID: 11861865
[TBL] [Abstract][Full Text] [Related]
19. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
20. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
